Clinical Trials: Page 146
-
Bellerophon Therapeutics moves PAH treatment into phase II
This add-on therapy could help patients who need additional support despite receiving standard-of-care treatment.
By Nicole Gray • June 20, 2014 -
Pfizer expands immuno-oncology research through Cellectics parnership
Pfizer is expanding oncology research by collaborating with Cellectics, which brings a unique immuno-oncology research platform to the partnership.
By Nicole Gray • June 19, 2014 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
NICE: More novel anticoagulant use could reduce strokes
The British agency has recommended adding novel anticoagulants to formularies throughout the UK.
By Nicole Gray • June 18, 2014 -
Gardasil approved in EU for prevention of anal cancer
The drug now has an expanded therapeutic role in Europe that also includes HPV prevention in adolescents.
By Nicole Gray • June 18, 2014 -
Pfizer, Novartis push for approval of meningitis vaccines
The two companies each have developed a vaccine to prevent a virulent form of meningitis.
By Nicole Gray • June 18, 2014 -
Pfizer expands research capacity with Cambridge, MA location
The firm is setting up a mega-research facility, bringing together industry, academic and the hospital system to collaborate on therapeutic innovation.
By Nicole Gray • June 18, 2014 -
New prescription erectile dysfunction cream introduced to UK
Vitaros (alprostadil cream) is the first cream available for treating erectile function.
By Nicole Gray • June 18, 2014 -
JNJ partners with Viiv to create new combo HIV drug
The medication could end up rivaling Atripla.
By Nicole Gray • June 17, 2014 -
Study: No apparent benefit in reducing blood pressure below 'normal' range
The massive survey followed more than 4,400 people over two-plus decades.
By Randy Lilleston • June 17, 2014 -
Intarcia presents positive phase III data on a once-yearly diabetes drug
The new therapy may be the key to controlling high blood sugar levels. Intarcia presented positive data at ADA 2014.
By Nicole Gray • June 17, 2014 -
Sanofi, Medtronic team up to offer options for diabetes patients
The new partnership focuses on innovative drug-device breakthroughs.
By Nicole Gray • June 17, 2014 -
OncoMed halts phase I studies of cancer drugs, but aims to reinitiate
Ths company, which is testing a novel approach to treating cancer at the stem-cell level, is determined to continue development.
By Nicole Gray • June 17, 2014 -
Insulin 300 performs well in phase III trials
Will it beat its competitors?
By Nicole Gray • June 17, 2014 -
Deep Dive
As diabetes soars, so do research and treatment options
Currently, about 180 drugs are in development to address the diabetes-related challenges that persist despite available treatments.
By Nicole Gray • June 16, 2014 -
NICE reverses stance on skin cancer treatment after reviewing new survival data
The panel changed its decision of four months ago based on positive survival data extending out three years.
By Nicole Gray • June 16, 2014 -
Parion, Santen bring dry eye drug to Asian markets
The drug has a novel mode of action and will help Parion build an Asian distribution network with a new partner.
By Nicole Gray • June 13, 2014 -
Deep Dive
Small companies may be key to big advances in malaria treatment
Malaria remains a major killer worldwide, and treatments quickly become ineffective because of resistance. On an industry level, smaller firms are taking on that challenge.
By Nicole Gray • June 13, 2014 -
Protein Sciences boosts influenza vaccine availability, distribution
In response to healthcare professionals who want access to Flublok ahead of the 2014-15 flu season, the company will make its recombinant vaccine available as early as September.
By Nicole Gray • June 13, 2014 -
X-Chem, Pfizer team up on orphan drug development
The collaboration pairs two companies that are powerful in different ways.
By Nicole Gray • June 13, 2014 -
Critics slam European Medicines Agency on transparency issues
BMJ, the Cochrane Collaboration and the AllTrials campaign are among several groups that have accused the EMA of trampling on the rights of researchers and the public.
By Nicole Gray • June 13, 2014 -
Lilly's Cyramza fails in phase III liver cancer trials, but sees a way forward
Although the drug failed to show statistical results for survival advantage in patients with advanced liver cancer, there were some meaningful results.
By Nicole Gray • June 13, 2014 -
AstraZeneca breathes new life into its respiratory portfolio
The company has acquired rights to a drug developed by Synairgen and is reporting positive phase II results on its psoriatric arthritis drug.
By Nicole Gray • June 13, 2014 -
New statins being developed to reduce side effects
The fact that using statins to significantly decrease the risk of CVD can increase the risk of diabetes is counterintuitive, but it is real.
By Nicole Gray • June 12, 2014 -
FDA delays review date for Orexigen's obesity drug
With almost 10,000 study subjects, Orexigen is responding to the federal agency's request for rigorous evidence to support their resubmitted NDA.
By Nicole Gray • June 12, 2014 -
Researchers uncover protein that drives resistance to cancer treatment
A drug that has been approved for the treatment of myelogenous leukemia may help block resistance in Tarceva-treated lung cancer patients and extend lifespan.
By Nicole Gray • June 12, 2014
Previous
